Dr. Mélissa Sourioux, Axoltis Pharma – Preclinical R&D Project Manager, will participate to Brain & Brain PET 2022, one of the top conferences in Neuroscience research which will take place in Glasgow, Scotland, on May 29th – June 1st. Dr. Sourioux will present results showing that Axoltis’ peptide NX210c improves synaptic recovery following ischemia in vitro and  demonstrate the rationale behind the use of NX210c in cognitive impairment due to long COVID.